Total Payments
$254,863
2024 Payments
$1,765
Companies
40
Transactions
562
Medicare Patients
9,827
Medicare Billing
$394,152
Payment Breakdown by Category
Other$194,303 (76.2%)
Travel$23,350 (9.2%)
Consulting$20,436 (8.0%)
Food & Beverage$16,691 (6.5%)
Education$83.78 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $193,703 | 67 | 76.0% |
| Travel and Lodging | $23,350 | 69 | 9.2% |
| Consulting Fee | $20,436 | 8 | 8.0% |
| Food and Beverage | $16,691 | 413 | 6.5% |
| Honoraria | $600.00 | 1 | 0.2% |
| Education | $83.78 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $125,145 | 146 | $0 (2023) |
| PFIZER INC. | $38,013 | 100 | $0 (2024) |
| Novo Nordisk Inc | $34,746 | 28 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $13,946 | 13 | $0 (2023) |
| Amgen Inc. | $9,020 | 34 | $0 (2024) |
| PORTOLA PHARMACEUTICALS, INC. | $6,958 | 7 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $6,274 | 5 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $4,700 | 36 | $0 (2024) |
| Aralez Pharmaceuticals US Inc. | $4,299 | 11 | $0 (2017) |
| Boston Scientific Corporation | $3,687 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,765 | 36 | PFIZER INC. ($392.86) |
| 2023 | $10,794 | 51 | SANOFI-AVENTIS U.S. LLC ($4,703) |
| 2022 | $16,205 | 48 | Janssen Pharmaceuticals, Inc ($14,695) |
| 2021 | $18,739 | 50 | Janssen Pharmaceuticals, Inc ($15,319) |
| 2020 | $17,227 | 27 | Janssen Pharmaceuticals, Inc ($9,170) |
| 2019 | $52,854 | 100 | Janssen Pharmaceuticals, Inc ($45,334) |
| 2018 | $73,498 | 125 | Novo Nordisk Inc ($32,116) |
| 2017 | $63,780 | 125 | Janssen Pharmaceuticals, Inc ($20,184) |
All Payment Transactions
562 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $117.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $37.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $49.26 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $144.19 | General |
| 10/11/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $39.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $34.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $41.55 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $121.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $95.15 | General |
| Category: DIABETES | ||||||
| 09/12/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $81.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/26/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/21/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $88.53 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $33.24 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/29/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $42.64 | General |
| Category: Immunology | ||||||
| 07/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $42.39 | General |
| 07/24/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $144.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/17/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $37.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/17/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.72 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 06/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/30/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $36.19 | General |
| 05/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: DIABETES | ||||||
| 05/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/02/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $37.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $35.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,202 | 2,690 | $495,958 | $93,364 |
| 2022 | 18 | 2,558 | 3,120 | $560,384 | $103,226 |
| 2021 | 19 | 2,644 | 3,259 | $555,209 | $99,099 |
| 2020 | 18 | 2,423 | 3,048 | $538,099 | $98,462 |
Total Patients
9,827
Total Services
12,117
Medicare Billing
$394,152
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 214 | 235 | $75,905 | $21,260 | 28.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 87 | 167 | $36,239 | $11,266 | 31.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 139 | 139 | $57,407 | $8,449 | 14.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 51 | $22,134 | $6,777 | 30.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 768 | 943 | $53,751 | $6,186 | 11.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 41 | $25,309 | $5,832 | 23.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $23,296 | $5,368 | 23.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 44 | $19,089 | $4,867 | 25.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 229 | 230 | $49,910 | $3,810 | 7.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 53 | 53 | $11,448 | $3,650 | 31.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 35 | $10,885 | $3,550 | 32.6% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 42 | 42 | $20,748 | $2,993 | 14.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 229 | 230 | $46,000 | $2,536 | 5.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 48 | 237 | $15,405 | $2,047 | 13.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 14 | $3,500 | $1,434 | 41.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 14 | $4,480 | $1,297 | 28.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 95 | 95 | $13,300 | $1,102 | 8.3% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2023 | 24 | 24 | $3,960 | $582.00 | 14.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 56 | 56 | $3,192 | $357.22 | 11.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 182 | 212 | $68,476 | $18,516 | 27.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 25 | 65 | $44,070 | $12,308 | 27.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 165 | 165 | $68,145 | $10,492 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 65 | 70 | $30,380 | $9,518 | 31.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 58 | 103 | $32,033 | $8,861 | 27.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 1,007 | 1,224 | $69,768 | $8,282 | 11.9% |
About Dr. Daniel Fintel, MD
Dr. Daniel Fintel, MD is a Cardiovascular Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992740328.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Fintel, MD has received a total of $254,863 in payments from pharmaceutical and medical device companies, with $1,765 received in 2024. These payments were reported across 562 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($193,703).
As a Medicare-enrolled provider, Fintel has provided services to 9,827 Medicare beneficiaries, totaling 12,117 services with total Medicare billing of $394,152. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Chicago, IL
- Active Since 06/19/2006
- Last Updated 07/02/2009
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1992740328
Products in Payments
- XARELTO (Drug) $125,294
- ELIQUIS (Drug) $37,840
- Victoza (Drug) $14,022
- Ozempic (Drug) $9,424
- Repatha (Biological) $8,512
- BEVYXXA (Drug) $6,958
- PRALUENT (Drug) $6,586
- PRALUENT ALIROCUMAB INJECTION (Biological) $6,274
- YOSPRALA (Drug) $4,299
- WATCHMAN (Device) $2,816
- LOKELMA (Drug) $2,679
- FARXIGA (Drug) $1,489
- THERAPIES (Device) $870.56
- LEQVIO (Drug) $755.05
- Sotalol Hydrochloride (Drug) $600.00
- ENTRESTO (Drug) $584.68
- VYNDAQEL (Drug) $492.00
- JARDIANCE (Drug) $420.28
- CHANTIX (Drug) $388.50
- VOQUEZNA (Drug) $372.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chicago
Sandeep Nathan
Cardiovascular Disease — Payments: $950,057
Cardiovascular Disease $950,057
Michael Davidson
Cardiovascular Disease — Payments: $636,827
Cardiovascular Disease $636,827
Jonathan Rich, M.d, M.D
Cardiovascular Disease — Payments: $597,351
Cardiovascular Disease $597,351
Sanjiv Shah, Md, MD
Cardiovascular Disease — Payments: $448,175
Cardiovascular Disease $448,175
Boaz Avitall
Cardiovascular Disease — Payments: $337,061
Cardiovascular Disease $337,061
Adhir Shroff, M.d, M.D
Cardiovascular Disease — Payments: $231,800
Cardiovascular Disease $231,800